Evidence map›Paper›PMID 41927282›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Dosimetry Analysis of

Zachary Ells, Catherine Meyer, Koichiro Kimura, Holly Wilhalme, Minsong Cao, Vinicius B Ludwig, Lena M Unterrainer, David Sennung, Rejah Nabong, Carol Felix and 6 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zachary EllsDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California; zells@mednet.ucla.edu.
Catherine MeyerDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Koichiro KimuraDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Holly WilhalmeDepartment of Medicine Statistical Core, UCLA, Los Angeles, California.
Minsong CaoDepartment of Radiation Oncology, UCLA, Los Angeles, California; and.
Vinicius B LudwigDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Lena M UnterrainerDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
David SennungDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Rejah NabongDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Carol FelixDepartment of Radiation Oncology, UCLA, Los Angeles, California; and.
Luca F ValleDepartment of Radiation Oncology, UCLA, Los Angeles, California; and.
Anthony DaleyDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Johannes CzerninDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Magnus DahlbomDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Amar U KishanDepartment of Radiation Oncology, UCLA, Los Angeles, California; and.
Jeremie CalaisDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The phase 2 LUNAR trial randomized (1:1) patients with oligorecurrent hormone-sensitive prostate cancer to neoadjuvant [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic NeoplasmsRadioisotopesAgedHumansMaleMiddle AgedNeoplasm MetastasisOrgans at RiskPositron Emission Tomography Computed TomographyProstate-Specific AntigenRadiometrySingle Photon Emission Computed Tomography Computed TomographyDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadioisotopes177Lu177Lu-PSMA-I&Tdosimetryoligorecurrentprostate cancerPSMASBRTtheranostics

Identifiers

PMID41927282
PMCPMC13321929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.